Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial

By T. Eberlein. 2008

1,951 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/663bd464e424ca1530f4c0e17f8da8eeaa23d96c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. elliot k fishman
2. M. Tempero
3. J. Herman
4. A. Klein
5. M. Malafa
6. T. Conroy
7. P. Hammel
8. Michel Ducreux

Citations in the corpus

• Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. (2008, background): “Furthermore, the survival results compare favorably with data reported from modern adjuvant trials for resected pancreatic cancer.(2-3) We believe preoperative gemcitabine-based chemoradiation has two distinct advantages in this regard.”
• Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. (2008, result): “The results of this trial (RTOG 9704) are consistent with other phase 3 adjuvant trials evaluating the effect of gemcitabine, such as the recently reported CONKO-001 (Charité Onkologie) trial.(20) The CONKO-001 trial randomized patients with completely resected pancreatic cancer to 6 cycles of gemci”
• Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure (2012, unknown): “Variable Long-term survivors (overall), n (%) (n = 95) ≥5- and <10-year survivorship, n (%) (n = 62) ≥10-yr survivorship, n (%) (n = 33) Chi-square P-value Gender NS Female 42 (45) 30 (48) 12 (37) Male 53 (55) 32 (52) 21 (63) Tumor location NS Head 77 (81) 51 (82) 26 (79) Body 7 (7) 5 (8) 2 (6) Tail”
• Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. (2008, background): “[23], the use of gemcitabine after surgery prolongs the time to relapse by 6 months.”
• Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021, background): “001, log rank).(127) Final results from this study showed median OS to be improved significantly for patients in the gemcitabine arm (22.”
• Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “The results of the CONKO-001 trial comparing gemcitabine to observation confirmed the benefit of adjuvant chemotherapy [29].”
• Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. (2013, methodology): “4 A sample size of 184 patients in each group was required to detect an improvement in disease-free survival of 6 months using gemcitabine, with a bilateral 5% type I error and a power of 90%, and assuming (1) a 20% dropout rate attributable to ineligibility or early dropout; (2) a 3-year recruitmen”
• Recent progress in pancreatic cancer (2013, methodology): “The benefit of adjuvant systemic chemotherapy was evaluated in the Charit e Onkologie (CONKO)-001 trial in which 354 patients were randomized to either observation or adjuvant gemcitabine given intravenously (IV) for a total of 6 cycles.(144) Disease-free survival (DFS) and overall survival (OS) wer”